Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Giancarlo Icardi; Andrea Orsi; Antonella Ceravolo; Filippo Ansaldi

doi:10.4161/8.1.18419

Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Giancarlo Icardi, Andrea Orsi, Antonella Ceravolo, Filippo Ansaldi

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults

Original language	English
Pages (from-to)	69-77
Number of pages	9
Journal	Human Vaccines and Immunotherapeutics
Volume	8
Issue number	1
DOIs	https://doi.org/10.4161/8.1.18419
Publication status	Published - Jan 2012

Keywords

Acceptability
Immunogenicity
Influenza vaccine
Intradermal
Micro injection system
Safety
Tolerability

ASJC Scopus subject areas

Immunology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.4161/8.1.18419

Cite this

@article{a60911aaa10e47bba6ea19428f8e8b92,

title = "Current evidence on intradermal influenza vaccines administered by Soluvia{\texttrademark} licensed micro injection system",

abstract = "Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults ",

keywords = "Acceptability, Immunogenicity, Influenza vaccine, Intradermal, Micro injection system, Safety, Tolerability",

author = "Giancarlo Icardi and Andrea Orsi and Antonella Ceravolo and Filippo Ansaldi",

year = "2012",

month = jan,

doi = "10.4161/8.1.18419",

language = "English",

volume = "8",

pages = "69--77",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Taylor and Francis Inc.",

number = "1",

}

TY - JOUR

T1 - Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

AU - Icardi, Giancarlo

AU - Orsi, Andrea

AU - Ceravolo, Antonella

AU - Ansaldi, Filippo

PY - 2012/1

Y1 - 2012/1

N2 - Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults

AB - Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults

KW - Acceptability

KW - Immunogenicity

KW - Influenza vaccine

KW - Intradermal

KW - Micro injection system

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84857196747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857196747&partnerID=8YFLogxK

U2 - 10.4161/8.1.18419

DO - 10.4161/8.1.18419

M3 - Article

AN - SCOPUS:84857196747

VL - 8

SP - 69

EP - 77

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 1

ER -

Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this